Indeed, neutralizing antibodies to TGFβ, inhibitors to TGFβ Receptor I (TβRI), antisense nucleotides and ligand traps (for TGFβ and other family members) are currently in clinical trial for the treatment of human cancers making them easily transferable to the context of B-ALL. Here, TGFB1 is linked to acute lymphoblastic leukemia.